NASDAQ:ANIK Anika Therapeutics (ANIK) Stock Price, News & Analysis $20.83 -0.26 (-1.23%) As of 10:47 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Anika Therapeutics Stock (NASDAQ:ANIK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Anika Therapeutics alerts:Sign Up Key Stats Today's Range$20.60▼$21.3450-Day Range$19.10▼$21.7852-Week Range$9.01▼$22.88Volume14,021 shsAverage Volume112,747 shsMarket Capitalization$278.71 millionP/E RatioN/ADividend YieldN/APrice Target$22.00Consensus RatingHold Company Overview Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid. Anika’s orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid. The company also offers Tactoset, an injectable bone void filler intended for use in orthopedic procedures. Its broader product offerings have included solutions for surgical, wound-care and other medical applications. Founded in 1983, Anika serves healthcare providers and patients in the United States and international markets through direct commercial operations and distribution partners. The company is headquartered in Bedford, Massachusetts, and has built its business around developing and commercializing medical products that use its expertise in hyaluronic acid and other biomaterials.AI Generated. May Contain Errors. Read More Anika Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreANIK MarketRank™: 2.693948280455 of 5 starsAnika Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 389th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingAnika Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Anika Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Anika Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth107.14% Earnings GrowthEarnings for Anika Therapeutics are expected to grow by 107.14% in the coming year, from $0.14 to $0.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is 1,030.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 35.76.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is 1,030.00, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 204.69.Price to Earnings Growth RatioAnika Therapeutics has a PEG Ratio of 14.71. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Anika Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.12% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 4.42.Change versus previous monthShort interest in Anika Therapeutics has recently decreased by 3.73%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.50 News SentimentAnika Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Anika Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $20,750.00 in company stock, which represents 0.0074% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,750.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.08% of the stock of Anika Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Anika Therapeutics' insider trading history. Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIK Stock News HeadlinesAnika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026October 22 at 4:01 PM | globenewswire.comCritical Comparison: Anika Therapeutics (NASDAQ:ANIK) and ADMA Biologics (NASDAQ:ADMA)October 19, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 23 at 1:00 AM | InvestorPlace (Ad)Anika Therapeutics (NASDAQ:ANIK) Shares Break Above Two Hundred Day Moving Average - What's Next?October 16, 2026 | americanbankingnews.comAnika (ANIK) Q2 2026 Earnings Call TranscriptAugust 8, 2026 | finance.yahoo.comAnika Therapeutics Lifts Outlook After Margin SurgeAugust 2, 2026 | tipranks.comAnika Therapeutics (ANIK) Stock Fair Value Rises After Q2 Beat And Higher GuidanceAugust 2, 2026 | finance.yahoo.comThese 2 biotech stocks hit new 52-week highs today – and CORT clocked its best day in nearly 16 monthsJuly 30, 2026 | msn.comSee More Headlines ANIK Stock Analysis - Frequently Asked Questions How have ANIK shares performed this year? Anika Therapeutics' stock was trading at $9.61 at the start of the year. Since then, ANIK stock has increased by 119.5% and is now trading at $21.09. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics Inc. (NASDAQ:ANIK) issued its quarterly earnings results on Wednesday, July, 29th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.39. The biotechnology company had revenue of $32.61 million for the quarter, compared to analyst estimates of $29.21 million. Anika Therapeutics had a positive trailing twelve-month return on equity of 0.20% and a negative net margin of 3.14%. Read the conference call transcript. Who are Anika Therapeutics' major shareholders? Top institutional shareholders of Anika Therapeutics include Assenagon Asset Management S.A. (0.30%). Insiders that own company stock include John B Henneman III, Gary P Fischetti and Stephen D Griffin. View institutional ownership trends. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anika Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Delta Air Lines (DAL), Advanced Micro Devices (AMD) and Starbucks (SBUX). Company Calendar Last Earnings7/29/2026Today10/23/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ANIK's financial health is in the Green zone, according to TradeSmith. ANIK has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ANIK CIK898437 Webwww.anika.com Phone(781) 457-9000Fax781-305-9720Employees235Year Founded1992Price Target and Rating Average Price Target for Anika Therapeutics$22.00 High Price Target$23.00 Low Price Target$21.00 Potential Upside/Downside+5.0%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E Ratio149.72 P/E Growth14.71Net Income-$10.88 million Net Margins-3.14% Pretax Margin-2.41% Return on Equity0.20% Return on Assets0.15% Debt Debt-to-Equity RatioN/A Current Ratio4.48 Quick Ratio3.19 Sales & Book Value Annual Sales$112.82 million Price / Sales2.49 Cash FlowN/A Price / Cash FlowN/A Book Value$9.95 per share Price / Book2.11Miscellaneous Outstanding Shares13,380,000Free Float11,766,000Market Cap$280.46 million OptionableOptionable Beta0.21 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:ANIK) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
